Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 217

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Effects of n-3 Polyunsaturated Fatty Acids on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardiomyopathy

Open access
Nodari, Savina, Triggiani, Marco, Campia, Umberto, Manerba, Alessandra, Milesi, Giuseppe, Cesana, Bruno M., Gheorghiade, Mihai, Dei Cas, Livio · 2011 · Journal of the American College of Cardiology

Abstract

OBJECTIVES This study was designed to test the effects of n-3 polyunsaturated fatty acids (PUFAs) on left ventricular (LV) systolic function in chronic heart failure (HF) due to nonischemic dilated cardiomyopathy (NICM). BACKGROUND One hundred thirty-three patients with NICM and minimal symptoms on standard therapy were randomized to 2 g of n-3 PUFAs or placebo. LV function and functional capacity were assessed prospectively by echocardiography and cardiopulmonary exercise testing at baseline and at 12 months after randomization. METHODS Patients with chronic HF due to NICM and minimal symptoms while receiving evidence-based therapy were enrolled. LV function and functional capacity were assessed prospectively by echocardiography, cardiopulmonary exercise test, and New York Heart Association functional class at baseline and at 12 months after randomization to either 2 g of n-3 PUFAs or placebo. RESULTS At 12 months after randomization, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to: 1) LV ejection fraction (increased by 10.4% and decreased by 5.0%, respectively); 2) peak VO(2) (increased by 6.2% and decreased by 4.5%, respectively); 3) exercise duration (increased by 7.5% and decreased by 4.8%, respectively); and 4) mean New York Heart Association functional class (decreased from 1.88 ± 0.33 to 1.61 ± 0.49 and increased from 1.83 ± 0.38 to 2.14 ± 0.65, respectively). The hospitalization rates for HF were 6% in the n-3 PUFAs and 30% in the placebo group (p = 0.0002). CONCLUSIONS In patients with NICM and minimal symptoms in response to evidence-based medical therapy, n-3 PUFAs treatment increases LV systolic function and functional capacity and may reduce hospitalizations for HF. Given these promising results, larger studies are in order to confirm our findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2010.11.017

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 14

  1. Mori, 2000, Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men, Circulation, 102, 1264, 10.1161/01.CIR.102.11.1264 · DOI · Paper page
  2. Grimsgaard, 1998, Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans, Am J Clin Nutr, 68, 52, 10.1093/ajcn/68.1.52 · DOI · Paper page
  3. McVeigh, 1994, Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus, Arterioscler Thromb, 14, 1425, 10.1161/01.ATV.14.9.1425 · DOI · Paper page
  4. Duda, 2009, Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction, Cardiovasc Res, 81, 319, 10.1093/cvr/cvn310 · DOI · Paper page
  5. Kirkpatrick, 2007, Echocardiography in heart failure: applications, utility, and new horizons, J Am Coll Cardiol, 50, 381, 10.1016/j.jacc.2007.03.048 · DOI · Paper page
  6. Ferrari, 1995, Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure, Circulation, 92, 1479, 10.1161/01.CIR.92.6.1479 · DOI · Paper page
  7. Marangoni, 2004, A method for the direct evaluation of the fatty acid status in a drop of blood from a fingertip in humans: applicability to nutritional and epidemiological studies, Anal Biochem, 326, 267, 10.1016/j.ab.2003.12.016 · DOI · Paper page
  8. Vargiu, 2010, Enhancement of shortening velocity, power, and acto-myosin crossbridge (CB) kinetics following long-term treatment with propionyl-L-carnitine, coenzyme Q10, and omega-3 fatty acids in BIO TO-2 cardiomyopathic Syrian hamsters papillary muscle, Biofactors, 36, 229, 10.1002/biof.95 · DOI
  9. Vargiu, 2008, Positive inotropic effect of coenzyme Q10, omega-3 fatty acids and propionyl-L-carnitine on papillary muscle force-frequency responses of BIO TO-2 cardiomyopathic Syrian hamsters, Biofactors, 32, 135, 10.1002/biof.5520320116 · DOI
  10. Berecki, 2007, Dietary fish oil reduces the incidence of triggered arrhythmias in pig ventricular myocytes, Heart Rhythm, 4, 1452, 10.1016/j.hrthm.2007.07.015 · DOI
  11. Pepe, 2002, Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function, Circulation, 105, 2303, 10.1161/01.CIR.0000015604.88808.74 · DOI · Paper page
  12. Duda, 2009, Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential, Cardiovasc Res, 84, 33, 10.1093/cvr/cvp169 · DOI
  13. Duda, 2007, Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload, Cardiovasc Res, 76, 303, 10.1016/j.cardiores.2007.07.002 · DOI
  14. Morgan, 2006, Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure, Am J Cardiol, 97, 547, 10.1016/j.amjcard.2005.08.075 · DOI

Cited by

See all 217

Metadata

Authors
Nodari, S., Triggiani, M., Campia, U., Manerba, A., Milesi, G., Cesana, B. M., Gheorghiade, M., & Dei Cas, L.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2011-02
Volume
57
Issue
7
Pages
870-879
ISSN
0735-1097 (ISSN-L)
OpenAlex
W1980857378
Cited by
217
References
7
FWCI
24.35
Type
journal article
Language
en
Open access
bronze
Licence
Funders
Università degli Studi di Brescia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.